What are the benefits of canagliflozin in the treatment of type 2 diabetes mellitus (DM)?

Updated: Jul 13, 2021
  • Author: Romesh Khardori, MD, PhD, FACP; Chief Editor: George T Griffing, MD  more...
  • Print

FDA approval of canagliflozin was based on global phase 3 clinical trials that included over 10,000 patients. [238, 239] In a trial evaluating canagliflozin monotherapy efficacy and safety in 584 adults with type 2 diabetes mellitus inadequately controlled with diet and exercise, treatment for 26 weeks with canagliflozin 100 or 300 mg daily resulted in a statistically significant improvement in HbA1C with both doses compared with placebo. [244]

Canagliflozin add-on combination therapy to metformin and/or sulfonylureas showed a reduction in fasting glucose and a greater proportion of patients achieving an HbA1C level less than 7%. [245] Add-on therapy to insulin and comparative data to thiazolidinediones and to dipeptidyl peptidase-IV inhibitors have also shown improved postprandial glucose levels and HbA1C levels. [245]

In October 2019, canagliflozin received FDA approval for the treatment of diabetic kidney disease (DKD) and, in patients with type 2 diabetes and DKD, reduction in the risk of hospitalization for heart failure. Approval stemmed from the outcome of the phase 3 CREDENCE study, which found that at median 2.62-year follow-up, the risk of renal failure and cardiovascular events was lower in patients with type 2 diabetes and kidney disease who were treated with canagliflozin than in patients on placebo. [246]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!